Evaluation of a single dose of estradiol valerate on the duration of hospitalization and its consequences in patients with severe burns: A clinical trial
Phase 2
- Conditions
- burn.Burn and corrosion of head, face, and neck
- Registration Number
- IRCT20210524051384N7
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patient with severe burns (second or higher degree burns with an area of more than 20%)
Fill out the informed consent form
Acute burns have occurred in less than 24 hours.
Exclusion Criteria
Electric burns
Inhalation burns
People with a history of estrogen-dependent cancer (breast, uterus, ovary)
Pregnant and lactating people
taking phenobarbital, carbamazepine, ritonavir, rifampin,
People with a history of thrombophlebitis and thromboembolism.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Discharge time and speed of recovery. Timepoint: daily. Method of measurement: Based on patients' records.
- Secondary Outcome Measures
Name Time Method Discharge status. Timepoint: daily. Method of measurement: view of patient file.;Duration of hospitalization in the ICU. Timepoint: daily. Method of measurement: patient record.;Comparison of changes in inflammatory factor IL-6. Timepoint: on day 1 (before injection of estradiol valerate) and 3 and 7. Method of measurement: ELISA.;Itching rate. Timepoint: daily. Method of measurement: based on the patient's statements.;Comparison of changes in laboratory indices of serum levels of CRP, ferritin, LDH, CPK. Timepoint: On days 1, 3 and 7. Method of measurement: By laboratory kits.;INR, PT, PTT. Timepoint: On days 1, 3 and 7. Method of measurement: By laboratory kits.;Serum and blood transfusion. Timepoint: daily. Method of measurement: based on patient records.